HSCA Applauds FDA for Releasing New Data to Enable Generic Competition
Washington, DC (June 19, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement applauding the U.S. Food and Drug Administration (FDA) for releasing new data to help generic drug competitors:
Click here for the full statement.
Related Posts
HSCA Announces 2019 Board of Directors and Names GNYHA Ventures President Lee Perlman Board Chair
January 24, 2019
Washington, DC (January, 2019) – The Healthcare Supply Chain Association (HSCA)...
Group Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
January 28, 2020
Dear Commissioner Hahn, The undersigned groups share the Food and Drug...
HSCA Statement on House Committee on Homeland Security Hearing on the Coronavirus
March 11, 2020
Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA)...
Comments of the Healthcare Supply Chain Association (HSCA) on Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020
October 15, 2019
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...